Asymptomatic adults aged 50-77 in the United Kingdom, randomized to annual Galleri multi-cancer early detection (MCED) blood testing added to standard NHS cancer screening, or standard screening alone, followed for cancer diagnoses over multiple screening rounds.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening (Journal of Clinical Oncology, 2026 ASCO Annual Meeting). DOI 10.1200/JCO.2026.44.17_suppl.LBA100.
Three adult patients with stage IV cancers (breast, prostate, and melanoma) who self-administered fenbendazole, an over-the-counter veterinary dewormer with no FDA approval for any human use, alongside their own separately-received standard cancer treatment, as described in a since-retracted case series.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients" (Case Reports in Oncology). DOI 10.1159/000549387, PMID 41574240.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study (The Lancet). DOI 10.1016/S0140-6736(23)02268-7.
Laboratory cell-line panels (including 859 distinct cancer cell lines used to test selectivity) and mouse xenograft models of diffuse large B-cell lymphoma (DLBCL) — no human patients have been treated with this compound.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-Induced Cell Death (bioRxiv preprint). DOI 10.1101/2025.03.14.643404, PMID 40166243.
Case report, neoadjuvant checkpoint immunotherapy in glioblastoma (Nature Medicine) — reports ONE patient. DOI 10.1038/s41591-025-03512-1, PMID 40016450.
Adults with high-risk muscle-invasive or locally advanced urothelial (bladder) carcinoma, following radical surgical removal of the bladder (radical cystectomy or nephroureterectomy), randomized to adjuvant pembrolizumab or observation alone.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with advanced, DLL3-expressing neuroendocrine carcinomas, including small cell lung cancer, large cell neuroendocrine carcinoma of the lung, and extrapulmonary neuroendocrine carcinoma (a category including neuroendocrine prostate cancer), enrolled in a first-in-human, open-label, dose-escalation/dose-expansion trial (SKYBRIDGE, NCT05652686). A reported target enrollment of approximately 203 patients was not independently confirmed against the trial registry itself in this research pass.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
SKYBRIDGE trial registry (first-in-human study of PT217/peluntamig). NCT05652686.
Eligibility varies — review trial criteria.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.